<DOC>
	<DOCNO>NCT01766713</DOCNO>
	<brief_summary>Nonalcoholic fatty liver disease ( NAFLD ) represent spectrum disease range simple steatosis nonalcoholic steatohepatitis ( NASH ) , progressive form liver disease lead cirrhosis liver-related mortality person drink little alcohol . Nonalcoholic steatohepatitis ( NASH ) represent severe end spectrum characterize steatosis , balloon degeneration lobular inflammation without fibrosis . The etiology NASH completely understand , often associate obesity , type 2 diabetes , hyperlipidemia insulin resistance . Lipotoxicity , insulin resistance oxidative stress appear central pathogenesis NASH . Currently , FDA approve treatment NAFLD/NASH . Weight loss exercise recommend often difficult maintain lifestyle change long term therefore therapeutic agent investigate . Ezetimibe LDL lower agent work inhibition fat absorption small intestine . In study , propose treat 50 patient NASH either Ezetimibe placebo 24 week . After initial evaluation insulin sensitivity , MRI liver fat distribution liver biopsy , patient receive either 10 mg/day Ezetimibe placebo . Patients monitor regular interval symptoms liver disease , side effect Ezetimibe serum biochemical metabolic index . At end 24-weeks , patient repeat medical evaluation , liver MRI liver biopsy . Pre post treatment MRI-derived liver fat content , liver histology insulin sensitivity compare . The primary end point successful therapy improvement hepatic steatosis measure MRI . Secondary end point improvement insulin sensitivity , liver histology liver biochemistry .</brief_summary>
	<brief_title>Ezetimibe Versus Placebo Treatment Non-alcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>1 . Age entry least 18 year . 2 . Serum alanine ( ALT ) aspartate ( AST ) aminotransferase activity upper limit normal . 19 woman 30 men . 3 . Evidence hepatic steatosis liver fat ( &gt; 5 % ) MRI . 4 . Evidence definite suspect NASH 1 . Evidence ( definite ) steatohepatitis liver biopsy do within previous 12 month NASH activity score least 4 ( total possible score 8 ) include score least 1 steatosis , hepatocellular injury parenchymal inflammation . Histological criterion steatohepatitis include : ( 1 ) macrovesicular steatosis , ( 2 ) acinar zone 3 hepatocellular injury ( balloon degeneration ) , ( 3 ) parenchymal ( 4 ) portal inflammation . Additionally helpful , require , feature include presence ( 5 ) Mallory 's hyaline ( 6 ) pericellular and/or sinusoidal fibrosis predominantly involve zone 3 . If liver biopsy available within last 12 month , repeat biopsy may conduct unless considerable change body weight may change liver histologic parameter associate NASH 2 . Those suspected NASH undergone liver biopsy within last 12 month may undergo liver biopsy screen liver biopsy would qualify randomization either ezetimibe placebo arm meet histologic criterion NASH . 5 . Written informed consent . 1 . Evidence another form liver disease . 1 . Hepatitis B define presence hepatitis B surface antigen ( HBsAg ) . 2 . Hepatitis C define presence hepatitis C virus ( HCV ) RNA serum . 3 . Autoimmune hepatitis define antinuclear antibody ( ANA ) 1:160 great liver histology consistent autoimmune hepatitis previous response immunosuppressive therapy . 4 . Autoimmune cholestatic liver disorder define elevation alkaline phosphatase antimitochondrial antibody great 1:80 liver histology consistent primary biliary cirrhosis elevation alkaline phosphatase liver histology consistent sclerosing cholangitis . 5 . Wilson disease define ceruloplasmin limit normal liver histology consistent Wilson disease . 6 . Alpha1antitrypsin deficiency define alpha1antitrypsin level less normal liver histology consistent alpha1antitrypsin deficiency . 7 . Hemochromatosis define presence 3+ 4+ stainable iron liver biopsy homozygosity C282Y compound heterozygosity C282Y/H63D . 8 . Druginduced liver disease define basis typical exposure history . 9 . Bile duct obstruction show imaging study . 2 . History excess alcohol ingestion , average 30 gm/day ( 3 drink per day ) previous 10 year , history alcohol intake average great 10 gm/day ( 1 drink per day : 7 drink per week ) previous one year . 3 . Contraindications liver biopsy : platelet count &lt; 75,000/mm3 prothrombin time &gt; 16 second history bleed disorder 4 . Decompensated liver disease , ChildPugh score great equal 7 point 5 . History gastrointestinal bypass surgery ingestion drug know produce hepatic steatosis include corticosteroid , highdose estrogen , methotrexate , tetracycline amiodarone previous 6 month . 6 . Recent initiation change antidiabetic drug , include insulin , sulfonylurea , thiazolidinediones previous 90 day . 7 . Use ezetimibe agent class within 90 day prior randomization and/or liver biopsy . 8 . Significant systemic major illness liver disease , include congestive heart failure , coronary artery disease , cerebrovascular disease , pulmonary disease hypoxia , renal failure , organ transplantation , serious psychiatric disease , malignancy , opinion investigator would preclude treatment ezetimibe adequate follow . 9 . Positive test antiHIV . 10 . Active substance abuse , alcohol , inhale injection drug within previous one year . 11 . Pregnancy inability practice adequate contraception woman childbearing potential . 12 . Evidence hepatocellular carcinoma : alphafetoprotein level great 200 ng/ml and/or liver mass image study suggestive liver cancer . 13 . Any condition , , opinion investigator would impede competence compliance possibility hinder completion study . 14 . Serum creatinine &gt; 1.5 mg/dl . 15 . Contraindications ezetimibe use : 1 . History allergic reaction ezetimibe 2. patient acute liver injury unexplained persistent elevation ALT &gt; 500 U/L 3 . Women pregnant may become pregnant 4 . Nursing mother 16 . Contraindications MRI : 1 . The subject contraindication MR imaging , patient pacemaker , metallic cardiac valve , magnetic material surgical clip , implant electronic infusion pump condition would preclude proximity strong magnetic field . 2 . The subject history extreme claustrophobia 3 . The subject fit inside MR scanner cavity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>